Screener
Avalo Therapeutics AVTX Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Interest income, net | 2,761 | 1,097 | 3,564 | 2,244 |
| Total other (expense) income, net | (4,823) | (1,433) | (3,540) | 94 |
| Loss before taxes | (36,340) | (20,749) | (55,959) | (33,890) |
| Income tax expense | 18 | 16 | 29 | 24 |
| Net loss | $(36,358) | $(20,765) | $(55,988) | $(33,914) |
| Net loss per share of common stock, basic and diluted | $(0.83) | $(1.92) | $(1.75) | $(3.18) |
| Weighted average common shares outstanding | 43,602,044 | 10,829,760 | 31,919,388 | 10,673,200 |
| Comprehensive loss: |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's income tax?
- Avalo Therapeutics (AVTX) reported income tax of $18K in Q2 2026.
- How has Avalo Therapeutics's income tax changed year-over-year?
- Avalo Therapeutics's income tax increased by 12.5% year-over-year, from $16K to $18K.
- What is the long-term trend for Avalo Therapeutics's income tax?
- Over 3 years (2021 to 2025), Avalo Therapeutics's income tax has grown at a -5.6% compound annual growth rate (CAGR), from -$196K to $165K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Avalo Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude